Rapaflo reduces CP/CPPS symptoms, improves outcomes among men in mid-stage trial

WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial.

Data from the phase-2 study of the drug Rapaflo (silodosin) presented at the American Urological Association’s annual meeting showed that it reduced symptoms and improved outcomes in men with chronic prostatitis/pelvic pain syndrome, also known as CP/CPPS.

CP/CPPS is a common condition that causes persistent discomfort in the lower pelvic area, frequent and painful urination and difficult or painful ejaculation. The cause of the condition is unknown, but is not related to bacterial infection. As many as 10% of men in North America have had or will have experienced prostatitis symptoms, and 90% of those have CP/CPPS.